Oxford Genetics Secures GBP1 Million Investment for Gene Therapy Technologies

Synthetic biology company, Oxford Genetics announced that it has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies. Mercia Technologies is making the investment as part of its focus on supporting the creation, funding, and scaling of innovative technology businesses with growth potential. 

Oxford Genetics recently relocated to new, state-of-the-art facilities in Oxford Science Park. The move gives the team access to dedicated cell development suites and new technology capable of automating certain processes, allowing the company to scale its services in line with increasing customer demand, and reinforce its position in DNA design, protein expression, and virus and cell line engineering.